ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Fibroblasts, Dermal"

  • Abstract Number: 0966 • ACR Convergence 2025

    Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset

    kristina clark1, Xu Shiwen2, Xue Li2, Voon H. Ong3 and Christopher Denton4, 1Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, 2University College London, London, United Kingdom, 3Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 4University College London, UK, London, United Kingdom

    Background/Purpose: The cell surface protein GPR68 (ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and…
  • Abstract Number: L18 • ACR Convergence 2024

    CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis

    Wei Guo1, Zhaohua Li2, Dan Xu2 and Rong Mu2, 1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, 2Peking University Third Hospital, Beijing, China

    Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
  • Abstract Number: 0784 • ACR Convergence 2024

    RUNX1 Is Expressed in a Subpopulation of Dermal Fibroblasts and Is Increased with Systemic Sclerosis Disease Severity

    Rezvan Parvizi1, Zhiyun Gong2, Helen Jarnagin2, Tamar Abel2, Dillon Popovich3, Madeline Morrisson4, Tammara Wood5, Sasha Shenk6, Monique Hinchcliff7, jonathan Garlick6, Patricia Pioli8 and Michael Whitfield1, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Dartmouth College, Lebanon, NH, 3Dartmouth College, West Lebanon, NH, 4Geisel School of Medicine at Dartmouth College, Hanover, NH, 5Dartmouth, Hanover, NH, 6Tufts University, Boston, MA, 7Yale School of Medicine, Westport, CT, 8Geisel School of Medicine at Dartmouth, Lebanon, NH

    Background/Purpose: Systemic Sclerosis (SSc) skin fibrosis results in complex changes in transcriptional and signaling pathways in the skin. Through transcription factor activity network analyses, the…
  • Abstract Number: 2449 • ACR Convergence 2024

    Acid Reflux Triggers Type I Interferon and Persistent Epithelial-mesenchymal Transition in Esophageal Epithelial Cells. a Novel Microenvironment Contribution to the Pathogenesis of Systemic Sclerosis

    Safoura Zahed Mohajerani1, john ladbury1, Rebecca Ross2 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Gastroesophageal reflux disease (GERD) is a very common manifestation of scleroderma (SSc), affecting as high as 90% of patients, second only to Raynaud’s phenomenon.…
  • Abstract Number: 0785 • ACR Convergence 2024

    Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis

    Elizabeth Caves1, Agrani Dixit1, Anna Jussila2, Vivian Lei3, Hailey Edelman4, Muhammad Hamdan5, Ian Odell5, Monique Hinchcliff6, Radhika Atit7 and Valerie Horsley1, 1Yale School of Medicine, New Haven, CT, 2Stanford Medicine, Stanford, CA, 3University of North Carolina School of Medicine, Chapel Hill, 4Vanderbilt School of Engineering, New Haven, 5Yale School of Medicine, New Haven, 6Yale School of Medicine, Westport, CT, 7Case Western Reserve University College of Arts and Sciences, Cleveland

    Background/Purpose: Resident lipid-filled dermal adipocytes are depleted in both systemic sclerosis (SSc) and scleroderma mouse models, but mechanisms are poorly understood. We undertook studies in mouse…
  • Abstract Number: 2462 • ACR Convergence 2024

    A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis

    Enming Su1, Pei-Suen Tsou1, Mark Warnock2, Natalya Subbotina1, Kris Mann1, Sirapa Vichaikul1, Xianying Xing1, Enze Xing1, Olesya Plazyo1, Rachael Wasikowski1, Lam C. Tsoi3, Mark Weinberg4, Cory D. Emal5, Dinesh Khanna1, John Varga1, Thomas H. Sisson1, Johann Gudjonsson1 and Daniel Lawrence2, 1University of Michigan, Ann Arbor, MI, 2Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI, 4MDI, Ann Arbor, MI, 5EMU, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is a complex and heterogeneous condition characterized by progressive fibrosis in multiple organs. Currently, there is no known cure for SSc,…
  • Abstract Number: 0930 • ACR Convergence 2024

    The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts

    Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
  • Abstract Number: 2473 • ACR Convergence 2024

    Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study

    Shervin Assassi1, Ruhani Desai2, Jeffrey Browning3, Samuel Theodore1, Meng Zhang1, Brian Skaug1, Jerry Alonso1, Zsuzsanna McMahan1, Maureen Mayes1 and Minghua Wu1, 1UTHealth Houston Division of Rheumatology, Houston, TX, 2UTHealth Houston Division of Rheumatology, DeLand, FL, 3Boston University, Cambridge, MA

    Background/Purpose: Modified Rodnan Skin Score is a widely used outcome measure for skin involvement in systemic sclerosis (SSc). Its criterion validity (comparison to the gold…
  • Abstract Number: 0970 • ACR Convergence 2024

    Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity

    Rebecca Ross1, Poli Adi Narayanna Reddy2, Joseph Salvino2, Elton Zeqiraj3 and Francesco Del Galdo3, 1Medicine and Health, University of Leeds, Leeds, United Kingdom, 2The Wistar Institute, Philadelphia, PA, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Increased Type I IFN activation plays a key role in Scleroderma (SSc), Systemic Lupus Erythematosus and Inflammatory Myositis. Deubiquitylase (DUB) BRCC36 isopeptidase complex (BRISC)…
  • Abstract Number: 2643 • ACR Convergence 2024

    Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis

    Kristina Clark1, Corrado Campochiaro2, Emma Derrett-Smith3, Voon Ong4, Christopher Buckley5 and Christopher Denton6, 1University of Oxford, Oxford, United Kingdom, 2IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 3University College London Division of Medicine, Birmingham, United Kingdom, 4University College London, London, England, United Kingdom, 5Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 6University College London, Northwood, United Kingdom

    Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc).  TGFβ is a key growth factor driving myofibroblast formation in SSc.  The main…
  • Abstract Number: 1643 • ACR Convergence 2024

    Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts

    Helen Jarnagin1, Dillon Popovich2, Rezvan Parvizi3, Rosemary Gedert4, Lam C. Tsoi5, Rachael Wasikowski5, Zhiyun Gong1, Madeline Morrisson6, Laurent Perreard7, Fred Kolling IV7, Dinesh Khanna4, Johann Gudjonsson4 and Michael Whitfield3, 1Dartmouth College, Lebanon, NH, 2Dartmouth College, West Lebanon, NH, 3Geisel School of Medicine at Dartmouth, Hanover, NH, 4University of Michigan, Ann Arbor, MI, 5Michigan, Dept. of Dermatology, Ann Arbor, MI, 6Geisel School of Medicine at Dartmouth College, Hanover, NH, 7Geisel School of Medicine, Dartmouth College, Lebanon

    Background/Purpose: We generated a vertically integrated dataset on treatment naïve patients with dcSSc (diffuse Systemic Sclerosis) skin that includes bulk RNA-seq, single nuclei multiome, and…
  • Abstract Number: 2644 • ACR Convergence 2024

    Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis

    Kimberly Lakin1, Robert Spiera2, John Spivack1, Yaxia Zhang1, Jessica Gordon3 and dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 3Division of Rheumatology, Weill Cornell Medical College, New York, NY, 4Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that fibroblast CD34 is low and alpha-smooth muscle actin (aSMA) is high in severe diffuse cutaneous systemic sclerosis (dcSSc) skin,…
  • Abstract Number: 1770 • ACR Convergence 2024

    Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus

    Nalani Sachan1, Christina Firl2, Philip Carlucci3, Nicola Fraser2, Robert Clancy4 and Jill Buyon5, 1NYU Grossman School of Medicine, New York, NY, 2NYU Langone Health, New York, NY, 3New York University School of Medicine, New York, NY, 4Columbia University Medical Center, New York, NY, 5New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
  • Abstract Number: 1815 • ACR Convergence 2024

    Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel

    Lauren Reinke-Breen1, Laura Leys1, Sunhwa Kim2, Lauren Olson1, Anastasia Marinopoulos1, Chris Butler1, Jennifer Van Camp1 and Lisa Hazelwood1, 1AbbVie, North Chicago, IL, 2AbbVie, South San Francisco, CA

    Background/Purpose: Systemic sclerosis (SSc) is a chronic, progressive autoimmune disorder with significant morbidity and mortality. The lack of effective therapies for SSc is, in part,…
  • Abstract Number: 1818 • ACR Convergence 2024

    Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin

    Banafsheh Nazari1, Tracy Tabib2, Christina Morse3 and Robert Lafyatis2, 1UPMC-Mercy, Pittsburgh, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh

    Background/Purpose: Our previous single-cell RNA-sequencing study identified two major fibroblast subpopulations in healthy skin biopsies: SFRP2/DPP4 and FMO1/LSP1 fibroblasts¹. Additionally, we discovered that adventitial fibroblasts…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology